Executive SummaryIn the 2026 pharmaceutical landscape, the "low-hanging fruit" of drug discovery has been harvested. The industry is now focused on high-complexity targets: PROTACs, targeted protein degraders, and multi-specific oligonucleotides. These molecules require reagents that offer near-perf
THERMODYNAMIC ENGINEERING: THE "LOW-ENERGY" REACTION COORDINATEThe 2026 pharmaceutical industry is governed by the Principle of Kinetic Efficiency. Traditional cyclization reagents often require high temperatures (>150 ℃) or harsh catalysts that leave heavy carbon footprints.CAS 4637-24-5 serves as
THE 2026 PRECISION REVOLUTION: SITE-SELECTIVITYThe greatest challenge in 2026 medicinal chemistry is the Late-Stage Functionalization (LSF) of complex molecules. Traditional reagents often lack the "surgical" precision needed to target a specific C-H bond without affecting existing sensitive groups.